On the evening of April 13, Jiu'an Medical issued an annual report. During the reporting period, the company realized the main business income of 425.45 million yuan, an increase of 4.39% over the previous year; the operating cost was 291.62 million yuan, an increase of 6.52% over the previous year; the period cost was 210.1 million. Yuan, a year-on-year increase of 57.12%, net cash flow from operating activities was -68.92 million yuan, an increase of 7.45% over the previous year; basic earnings per share was 0.03 (yuan/share), an increase of 250.00% over the previous year. The profit distribution plan adopted is: based on 372,000,000 shares, a cash dividend of 0.20 yuan (tax) will be distributed to every 10 shares of all shareholders, and 0 shares (including tax) will be sent to the bonus shares, and no capital reserve will be transferred to the share capital.
View full text of the announcement
At present, Jiu'an Medical's main business income is divided into three parts: iHealth series product revenue, self-owned brand product income and ODM/OEM product income. Although the company's overall sales revenue is basically the same as in 2013, the proportion of revenue of the above three types of products is changing.
From the perspective of revenue, iHealth series products continued to grow rapidly in Europe and the United States in 2014, an increase of 67.44% over 2013. The traditional independent brands are increasingly competitive due to the increasingly fierce competition between online and offline, with a year-on-year decline of 22.63%; ODM/OEM product sales revenue It grew by 4.2% year-on-year, with little change. From the perspective of gross profit margin, ODM/OEM products have the lowest, 12.44%; iHealth series products have the highest, reaching 52.56%.
Jiu'an Medical put forward that “the future will continue to build a complete mobile internet economy ecosystemâ€. In September last year, it introduced a $25 million investment in Xiaomi. Liu Yi said that in the past, iHealth was only testing water sales in China. The sales volume in China was basically “zeroâ€. The cooperation with Xiaomi was the signal that iHealth officially entered the Chinese market.
Liu Yi said that mobile Internet+ is the opportunity for transformation. The transformation logic is based on selling hardware as a cut-off, accumulating sufficient users to form a supporting health and medical service system, and finally creating “hardware + application (APP)+ Cloud's personal health management platform.
According to a previously published study by TransparencyMarketResearch, the global market for wearable mobile health devices in 2012 was $2 billion, and by 2019 it will reach $5.8 billion, with a compound annual growth rate of 16.4%. Faced with the current fragmented market structure of the mobile medical industry, some analysts said that fierce competition is conducive to product innovation, and the market may form an oligopoly in the future.
Collagen is the most abundant protein in mammals, accounting for 25% to 30% of the total protein. It is widely present in all tissues from the body surface of lower vertebrates to mammalian bodies. Collagen monomers are long cylindrical proteins with a length of about 280 nm and a diameter of 1.4–1.5 nm. It consists of 3 polypeptide chains that are supercoiled around each other.
Collagen,Collagen Peptides,Collagen costco,Collagen Peptide Products
YT(Xi'an) Biochem Co., Ltd. , https://www.ytherblifes.com